The neurodegenerative process in AD is reflected in CSF biomarkers where reduced Aβ levels, along with elevated total tau (t-tau) and phosphorylated tau (p-tau) proteins, signify the ongoing neurodegenerative events. This evidence concerns the gene MAPT and Alzheimer disease.